Phio Pharmaceuticals Corp. (PHIO)

Market Cap	10.51M
Revenue (ttm)	n/a
Net Income (ttm)	-6.77M
Shares Out	4.80M
EPS (ttm)	-9.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,335
Open	2.100
Previous Close	2.140
Day's Range	2.050 - 2.240
52-Week Range	0.966 - 9.790
Beta	0.87
Analysts	Strong Buy
Price Target	9.00 (+310.96%)
Earnings Date	Aug 18, 2025

About PHIO

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also develop...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: PHIO
• Website: https://phiopharma.com

Analyst Forecast

According to 2 analysts, the average rating for PHIO stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 310.96% from the latest price.

Price Target

$9.0

(310.96% upside)

Analyst Consensus: Strong Buy